ALK-Abelló A/S

ALK-Abelló A/S

$22.05
2.83 (13.37%)
Other OTC
USD, DK
Biotechnology

AKBLF Price Chart

Basic
Market Cap$6.02B
Price$22.05
52 Week Range10.95-24.6
Beta0.59
Margins
Gross Profit Margin63.94%
Operating Profit Margin20.06%
Net Profit Margin14.58%
Valuation (TTM)
P/E Ratio42.81
Price to Sales Ratio6.41
Price to Book Ratio6.61
PEG Ratio2.89

Industry

Biotechnology

Sector

Healthcare

Full-Time Employees

2,806

IPO Date

2009-11-16T00:00:00.000Z

Description

ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including house dust mite, grass, tree, ragweed, and Japanese cedar. It also provides adrenaline auto-injectors for the treatment of severe allergic reactions; and manufactures products used in the diagnosis of allergies. The company offers GRAZAX, RAGWITEK, RAGWIZAX, MITICURE, ODACTRA, CEDARCURE, and ITULAZAX for the treatment of allergic rhinitis; and ACARIZAX for treating allergic rhinitis and allergic asthma. ALK-Abelló A/S was founded in 1923 and is headquartered in Hørsholm, Denmark.

Phone

45 45 74 75 76

Address

Boge Alle 6-8, Horsholm, 2970, DK

CIK